Search Within
S6826
Applied Filters:
Keyword:'S6826'
Showing 1-30 of 42 results for "S6826" within Papers
Jarogniew J Luszczki et al.
Epilepsy research, 90(3), 188-198 (2010-05-25)
The aim of this study was to characterize the anticonvulsant effects of stiripentol (STP) in combination with clobazam [CLB], and valproate [VPA]) in the mouse maximal electroshock (MES)-induced seizure model using the type I isobolographic analysis for parallel and non-parallel
Milena Djuric et al.
Epileptic disorders : international epilepsy journal with videotape, 13(1), 22-26 (2011-03-12)
The syndrome of malignant migrating partial seizures in infancy is a devastating, age-specific, epileptic encephalopathy, which still presents an aetiological, pathophysiological and therapeutic problem. In this study, we present two patients who were diagnosed with the disease, based on electroclinical
C Chiron et al.
Lancet (London, England), 356(9242), 1638-1642 (2000-11-23)
Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a
Marie-Clémence Verdier et al.
Therapie, 67(2), 157-160 (2012-08-02)
Stiripentol is a third generation antiepileptic, marketed since 2007 under the name of Diacomit(®). It is indicated, always in combination, in the treatment of severe myoclonic epilepsy in infancy or Dravet syndrome. Its pharmacokinetics is not linear. It is a
Jarogniew J Luszczki et al.
Epilepsia, 47(11), 1841-1854 (2006-11-23)
Isobolographic analysis was used to characterize the interactions between stiripentol (STP) and clonazepam (CZP), ethosuximide (ETS), phenobarbital (PB), and valproate (VPA) in suppressing pentylenetetrazole (PTZ)-induced clonic seizures in mice. The anticonvulsant and acute adverse (neurotoxic) effects of STP in combination
Catherine Chiron
Expert opinion on investigational drugs, 14(7), 905-911 (2005-07-19)
Stiripentol (STP) is a new antiepileptic compound produced by Biocodex. It is not structurally related to any of the other currently marketed antiepileptic products as it belongs to the group of aromatic allylic alcohols. It has recently been proved to
M Bebin et al.
Drugs, 48(2), 153-171 (1994-08-01)
In the past decade, several new antiepileptic drugs have been tested. Most recently, 5 new antiepileptic drugs have been launched onto European and US markets. These include vigabatrin, oxcarbazepine and lamotrigine in Europe, and felbamate and gabapentin in the US.
Selwyn S Jayakar et al.
Molecular pharmacology, 95(6), 615-628 (2019-04-07)
GABAA receptors (GABAARs) are targets for important classes of clinical agents (e.g., anxiolytics, anticonvulsants, and general anesthetics) that act as positive allosteric modulators (PAMs). Previously, using photoreactive analogs of etomidate ([3H]azietomidate) and mephobarbital [[3H]1-methyl-5-allyl-5-(m-trifluoromethyl-diazirynylphenyl)barbituric acid ([3H]R-mTFD-MPAB)], we identified two homologous
Screening of conventional anticonvulsants in a genetic mouse model of epilepsy.
Hawkins NA, et al.
Annals of Clinical and Translational Neurology, 4(5), 326-339 (2017)
Catherine Chiron
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 123-125 (2007-01-03)
Stiripentol (STP) is a new antiepileptic compound made by Biocodex. It recently proved to increase the GABAergic transmission in vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an
Mohamed N Aboul-Enein et al.
European journal of medicinal chemistry, 47(1), 360-369 (2011-11-29)
A series of stiripentol (STP) analogues namely, 2-[(1E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ylidene]-N-(aryl/H)hydrazinecarboxamides 7a-h, (±)-(5RS)-N-(aryl/H)-(1,3-benzodioxol-5-yl)-3-tert-butyl-4,5-dihydro-1H-pyrazole-1-carboxamides (±)-8a-h, and (±)-[(5RS)-(1,3-benzodioxol-5-yl)-3-tert-butyl-4,5-dihydro-1H-pyrazol-1-yl](aryl)methanones (±)-13a-f was synthesized by adopting appropriate synthetic routes and was pharmacologically evaluated in the preliminary anticonvulsant screens. The selected bioactive new chemical entities were subjected to ED(50)
Behrouz Kassaï et al.
Epilepsia, 49(2), 343-348 (2007-11-22)
Severe myoclonic epilepsy in infancy (SMEI) is a rare, but severe disorder with seizures typically resistant to conventional antiepileptic drugs. The objective of the present study was to systematically review the literature on the available treatments for SMEI. Databases searched
Carole Giraud et al.
Drug metabolism and disposition: the biological fate of chemicals, 34(4), 608-611 (2006-01-18)
A metabolic interaction between stiripentol (STP), an anticonvulsant agent that inhibits the activity of several cytochromes P450 (P450s), and clobazam (CLB), a 1,5-benzodiazepine, used in association with STP in severe myoclonic epilepsy in infancy was observed in vivo. This interaction
Greg L Plosker
CNS drugs, 26(11), 993-1001 (2012-09-29)
Stiripentol is an anticonvulsant used as adjunctive therapy with valproate and clobazam in the management of patients with severe myoclonic epilepsy of infancy (SMEI; Dravet syndrome), a rare form of epilepsy that develops in the first year of life and
HIGHLY SENSITIVE SYNCHRONOUS SPECTROFLUORIMETRIC METHOD FOR DETERMINATION OF STIRIPENTOL IN CAPSULES AND HUMAN URINE: APPLICATION TO IN-VITRO DRUG RELEASE AND WEIGHT VARIATION TEST.
Darwish HW, et al.
Digest Journal of Nanomaterials and Biostructures, 9(2), 819-829 (2014)
Catherine Chiron
Developmental medicine and child neurology, 53 Suppl 2, 16-18 (2011-04-29)
Dravet syndrome is a highly pharmaco-resistant form of epilepsy. Valproate and benzodiazepines are the first-line treatment but are usually insufficient therapeutic options. Lamotrigine, carbamazepine and high doses of intravenous phenobarbital can aggravate seizures and should be avoided. Topiramate, levetiracetam, bromide
Paolo Prunetti et al.
Current opinion in neurology, 24(2), 159-164 (2011-02-09)
There is a need for newer anti-epileptic drugs (AEDs) with improved efficacy and tolerability. This article reviews AEDs introduced since 2007 and investigational compounds in clinical development. Two recently introduced AEDs, stiripentol and rufinamide, have been licensed exclusively for orphan
Denise K Grosenbaugh et al.
Epilepsia, 54 Suppl 6, 103-105 (2013-09-06)
Benzodiazepines (BZDs), which enhance γ-aminobutyric acid (GABAA ) receptor-mediated inhibition, are the first-line therapy for treatment of status epilepticus (SE). However, pharmacoresistance to BZDs develops rapidly after SE initiation. This is due to an activity-dependent internalization of BZD-sensitive GABAA receptors
Atsushi Fujiwara et al.
Journal of anesthesia, 34(3), 373-381 (2020-03-20)
Antiepileptic drugs are used not only for the treatment of epilepsy but also for that of neuropathic pain. However, their action mechanisms have not always been well explained. Stiripentol, an effective antiepileptic drug indicated as a therapeutic for Dravet syndrome
Dezhi Cao et al.
Epilepsia, 53(7), 1140-1145 (2012-05-15)
We previously reported a mutant mouse carrying a severe myoclonic epilepsy in infancy (SMEI) mutation in Scn1a. In this study, we examined the susceptibility to hyperthermia-induced seizures of heterozygous Scn1a mutant mice (Scn1a(RX/+)) and wild-type (Scn1a(+/+) ) mice. Then we
Xingwang Zhang et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 62, 301-308 (2014-06-24)
Oral delivery of many drugs is plagued with limited solubility and/or poor stability. This paper aimed to explore the performance of polymeric mixed micelles on solubilization, stabilization and bioavailability enhancement with stiripentol as model drug. Stiripentol-loaded mixed micelles were prepared
Francesco Brigo et al.
The Cochrane database of systematic reviews, 1(1), CD009887-CD009887 (2014-02-04)
Nearly 30%of people with epilepsy do not have their seizures controlled with current treatments. Stiripentol is a new antiepileptic drug(AED) developed in France and recently approved by the European Medicines Agency (EMA) for the treatment of Dravet syndrome as an
Yushi Inoue et al.
Epilepsia, 50(11), 2362-2368 (2009-06-26)
To survey the treatment situation of Dravet syndrome in Japan and to compare this result with effectiveness of stiripentol (STP) add-on therapy in an open-label multicenter study. Medical records of patients with Dravet syndrome who visited the study institutions during
Stéphane Auvin et al.
Epilepsia, 54(12), 2082-2090 (2013-10-15)
After the first positive experimental data in rodents in the early 1970s demonstrating the anticonvulsant effect of stiripentol (STP), in vitro studies showed that STP acts directly on γ-aminobutyric acid A (GABAA ) receptors. Chloride influx is higher when these
Rima Nabbout et al.
Epilepsia, 52(7), e54-e57 (2011-05-17)
We aimed to test the efficacy of ketogenic diet (KD) in patients with Dravet syndrome (DS) not satisfactorily controlled by antiepileptic drugs (AEDs). We included prospectively 15 DS patients aged >3 years with partial response to AEDs including stiripentol. All
Elaine C Wirrell et al.
Epilepsia, 54(9), 1595-1604 (2013-07-16)
To review the efficacy and tolerability of stiripentol in the treatment of U.S. children with Dravet syndrome. U.S. clinicians who had prescribed stiripentol for two or more children with Dravet syndrome between March 2005 and 2012 were contacted to request
Theodor W May et al.
Therapeutic drug monitoring, 34(4), 390-397 (2012-06-30)
Stiripentol (STP) was approved as an orphan drug in 2007 in Europe as adjunctive therapy with valproic acid (VPA) and clobazam (CLB) for Dravet syndrome. Dravet syndrome is a highly pharmacoresistant form of epilepsy, which starts in early childhood. Data
The new antiepileptic drugs.
S Macleod et al.
Archives of disease in childhood. Education and practice edition, 92(6), 182-188 (2007-11-23)
Dana Merdariu et al.
Brain & development, 35(2), 177-180 (2012-04-24)
The syndrome of malignant migrating partial seizures of infancy (MMPSI) is characterized by early onset of multiple seizure types and overall poor prognosis. Seizures are markedly drug resistant and few reports have suggested the efficacy of some antiepileptic drugs. We
Jarogniew J Luszczki et al.
Naunyn-Schmiedeberg's archives of pharmacology, 374(1), 51-64 (2006-09-15)
The anticonvulsant effects produced by stiripentol (STP), carbamazepine (CBZ), and their combination in the maximal electroshock (MES)-induced seizures in mice were investigated using three-dimensional (3D) isobolographic analysis. With 3D isobolography, the combinations of both drugs at the fixed-ratios of 1:3
Page 1 of 2